Skip to the main content.

Early Parkinson’s Disease

MULTIPROTOCOL PROGRAM-LEVEL SUPPORT

Case Studies

Here you can edit the background of the section

Key Takeaways

  • The TemPo studies program consisted of four protocols.

  • The TemPo studies website and the study recruitment campaign took a sympathetic tone with the understanding that patients recently diagnosed, along with their loved ones, are looking to make the most of their time and quality of life in the face of this progressive disease.

  • BBK contributed to enrollment for the TemPo studies by consenting 17 referrals for screening, with an outcome of four patients that randomized into the study with a 6576% referral reach rate across studies within this program.
TemPo_rgb

 

Challenges 

 

  • Seeking “clinically probable PD” patients who have not yet received treatment
  • Placebo-control study design
  • Lack of patients in site panels given disease status — early stage
  • Concomitant or previous medication exclusions narrow the eligible population
  • A need to reach a broader audience, inclusive of caregivers, to find our ideal patient
HubSpot Video



 

HubSpot Video



 

Solutions and Impact

The website and study prescreener launched to the US patient audience for 14 months, garnering 1,639 referrals across three protocols — far exceeding the 760 initially projected.  

The study was further supported by call center outreach to referrals (that qualified for the study based on their prescreener responses) helping sites maintain a 6576% referral reach rate by contacting them prior to site assignment, verifying contact information and obtaining preferred contact methods. 

BBK contributed to enrollment for the TemPo studies by consenting 17 referrals for screening, with an outcome of 4 patients that randomized into the study.

  • Participants_ICON 1,639 QUALIFIED REFERRALS

  • Sites_ICON 136 SUPPORTED SITES

  • Countries-ICON-1 14 COUNTRIES

  • 4-Protocols_ICON-1 4 PROGRAM PROTOCOLS

__BBK-WEBSITE-ICONS-38

65–76% REFERRAL REACH RATE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

APEX Awards Nomination
The industry award judged entirely by HCPs

Selected as a finalist for the Pharmaceutical Executive APEX Awards — the only healthcare marketing awards judged entirely by healthcare professionals (HCPs) — we are honored to be recognized by those who understand what it takes to build trust in the Parkinson's disease community.

 

 

 

 

 

 

Download the PDF version of this case study today:

Subscribe to stay connected

Share this page:

Familial Amyloid Polyneuropathy — Neurology and Gene Therapy — Phase 3

case-studies-icon Case Studies

March 23, 2023

Pediatric Spinal Muscular Atrophy — Neurology and Rare Disease — Phase 2

case-studies-icon Case Studies

March 23, 2023

Major Depressive Disorder — Mental Health — Pivotal Phase 3 Study

case-studies-icon Case Studies

March 23, 2023

BBK Worldwide, LLC
117 Kendrick St., Suite 600
Needham, MA 02494 United States

        Terms & Conditions  Privacy Policy

        © 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.

        Facebook LinkedIn YouTube
        Facebook LinkedIn YouTube

        Terms & Conditions  Privacy Policy

        © 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.